Anne M Minihane1, Christopher K Armah2, Elizabeth A Miles3, Jacqueline M Madden3, Allan B Clark4, Muriel J Caslake5, Chris J Packard5, Bettina M Kofler2, Georg Lietz6, Peter J Curtis4, John C Mathers6, Christine M Williams2, Philip C Calder7. 1. Norwich Medical School, University of East Anglia, Norwich, United Kingdom; a.minihane@uea.ac.uk. 2. Hugh Sinclair Unit of Human Nutrition, Department of Food and Nutritional Sciences, University of Reading, Reading, United Kingdom; 3. Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; 4. Norwich Medical School, University of East Anglia, Norwich, United Kingdom; 5. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom; 6. Human Nutrition Research Centre, Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom; and. 7. Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; National Institute for Health Research (NIHR) Southampton Biomedical Research Centre at University Hospitals Southampton National Health Service (NHS) Foundation Trust and the University of Southampton, Southampton, United Kingdom.
Abstract
BACKGROUND: Although many randomized controlled trials (RCTs) have examined the effects of the n-3 (ω-3) fatty acids eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3) on blood pressure (BP) and vascular function, the majority have used doses of EPA+DHA of >3 g/d, which are unlikely to be achieved by dietary manipulation. OBJECTIVE: The objective was to examine, by using a retrospective analysis from a multicenter RCT, the impact of recommended EPA+DHA intakes achievable through diet on systolic and diastolic BPs and microvascular function in adults in the United Kingdom. METHODS: In a double-blind, placebo-controlled RCT, healthy men and women (n = 312) consumed a control oil or fish oil (FO) providing 0.7 or 1.8 g EPA+DHA/d, in random order, each for 8 wk. Fasting BP and microvascular function (using laser Doppler iontophoresis) were assessed and plasma collected for the quantification of markers of vascular function. Participants were retrospectively genotyped for the endothelial nitric oxide synthase (eNOS) rs1799983 variant. RESULTS: No effects of n-3 fatty acid treatment or any treatment × eNOS genotype interactions were evident in the group as a whole for any of the clinical or biochemical outcomes. Assessment of response according to hypertension status at baseline indicated a significant (P = 0.046) FO-induced reduction (mean: 5 mm Hg) in systolic BP, specifically in those with isolated systolic hypertension (n = 31). No dose response was observed. CONCLUSIONS: These findings indicate that in adults with isolated systolic hypertension, daily doses of EPA+DHA as low as 0.7 g show clinically meaningful BP reductions, which, at a population level, could be associated with lower cardiovascular disease risk. Confirmation of findings in an RCT in which participants are prospectively recruited on the basis of BP status is required to draw definite conclusions.
BACKGROUND: Although many randomized controlled trials (RCTs) have examined the effects of the n-3 (ω-3) fatty acids eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3) on blood pressure (BP) and vascular function, the majority have used doses of EPA+DHA of >3 g/d, which are unlikely to be achieved by dietary manipulation. OBJECTIVE: The objective was to examine, by using a retrospective analysis from a multicenter RCT, the impact of recommended EPA+DHA intakes achievable through diet on systolic and diastolic BPs and microvascular function in adults in the United Kingdom. METHODS: In a double-blind, placebo-controlled RCT, healthy men and women (n = 312) consumed a control oil or fish oil (FO) providing 0.7 or 1.8 g EPA+DHA/d, in random order, each for 8 wk. Fasting BP and microvascular function (using laser Doppler iontophoresis) were assessed and plasma collected for the quantification of markers of vascular function. Participants were retrospectively genotyped for the endothelial nitric oxide synthase (eNOS) rs1799983 variant. RESULTS: No effects of n-3 fatty acid treatment or any treatment × eNOS genotype interactions were evident in the group as a whole for any of the clinical or biochemical outcomes. Assessment of response according to hypertension status at baseline indicated a significant (P = 0.046) FO-induced reduction (mean: 5 mm Hg) in systolic BP, specifically in those with isolated systolic hypertension (n = 31). No dose response was observed. CONCLUSIONS: These findings indicate that in adults with isolated systolic hypertension, daily doses of EPA+DHA as low as 0.7 g show clinically meaningful BP reductions, which, at a population level, could be associated with lower cardiovascular disease risk. Confirmation of findings in an RCT in which participants are prospectively recruited on the basis of BP status is required to draw definite conclusions.
Authors: Cristina Razquin; Liming Liang; Estefanía Toledo; Clary B Clish; Miguel Ruiz-Canela; Yan Zheng; Dong D Wang; Dolores Corella; Olga Castaner; Emilio Ros; Fernando Aros; Enrique Gomez-Gracia; Miquel Fiol; José Manuel Santos-Lozano; Marta Guasch-Ferre; Lluis Serra-Majem; Aleix Sala-Vila; Pilar Buil-Cosiales; Monica Bullo; Montserrat Fito; Olga Portoles; Ramon Estruch; Jordi Salas-Salvado; Frank B Hu; Miguel A Martinez-Gonzalez Journal: Int J Cardiol Date: 2018-02-15 Impact factor: 4.164
Authors: Hylde Zirpoli; Chuchun L Chang; Yvon A Carpentier; Adina T Michael-Titus; Vadim S Ten; Richard J Deckelbaum Journal: Annu Rev Nutr Date: 2020-09-23 Impact factor: 11.848
Authors: Jeffery M Reddan; David J White; Helen Macpherson; Andrew Scholey; Andrew Pipingas Journal: Front Aging Neurosci Date: 2018-03-07 Impact factor: 5.750
Authors: Sara Bonafini; Alice Giontella; Angela Tagetti; Denise Marcon; Martina Montagnana; Marco Benati; Rossella Gaudino; Paolo Cavarzere; Mirjam Karber; Michael Rothe; Pietro Minuz; Franco Antonazzi; Claudio Maffeis; Wolf Hagen Schunck; Cristiano Fava Journal: Nutrients Date: 2018-11-05 Impact factor: 5.717